About Alys Pharmaceuticals
Alys Pharmaceuticals is a pioneering force in immuno-dermatology, poised to redefine the treatment landscape with cutting-edge science and a robust R&D-centric multi-platform pipeline.
Launched in February 2024, Alys emerges as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.
Alys has received a total of $100M financing from Medicxi.
Alys has been structured with an operational focus around each asset class, and with focus on the dermatology vertical for optimized leverage and impact
Vision and Mission
Transforming the treatment paradigm across dermatological indications.
These range from established indications such as atopic dermatitis to emerging categories like vitiligo, alopecia areata and chronic spontaneous urticaria. Beyond these, Alys is committed to addressing underserved indications like CTCL, mastocytosis and prevention of dermatological side effects of oncology therapies. With a focus on innovation and collaboration, Alys Pharmaceuticals aims to bring hope and transformative solutions to patients worldwide.